Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
The Cambridge-based biotech was co-founded by Atlas Ventures and CEO Alex Lugovsky to develop agonist antibodies for rare diseases, with a lead program in hereditary hemorrhagic telangiectasia.
The four highest doses of Eli Lilly’s blockbuster diabetes treatment Mounjaro will be in short supply through the rest of the month due to strong demand, according to the regulator.
Acorda Therapeutics becomes the latest biotechnology company in 2024 to go bankrupt and shutter its business, following years of financial difficulty. Merz Therapeutics will acquire two commercial medicines from Acorda for $185 million.
After sustaining a regulatory defeat in insomnia, Vanda Pharmaceuticals on Tuesday won the FDA’s approval for its atypical antipsychotic Fanapt for the treatment of manic or mixed episodes in adults with bipolar I disorder.
Genmab announced Wednesday it is buying ProfoundBio and its pipeline of next-generation antibody-drug conjugates being developed for gynecologic cancers and other solid tumors.
With second-generation antibody-drug conjugates, Eli Lilly, Daiichi Sankyo and others look to reduce toxicity and improve the magnitude and duration of response.
The new Cambridge, Mass.–based facility is about 460,000 square feet. Labs occupy nearly 50% of the space.
Read the latest overview of people coming and going from executive positions at biopharma companies that BioSpace covers.
Plus, another big buy points to strength of CDMO market and a new treatment for pulmonary arterial hypertension
Avenzo’s founders, who led Turning Point through its $4.1 billion sale to BMS, want to in-license three clinical-stage oncology candidates by early 2026.
Under the agreement, Ipsen nabs exclusive global rights for development and commercialization of Sutro Biopharma’s STRO-003, an antibody-drug conjugate which is completing the final stages of preclinical development.
The biotech’s personalized neoantigen vaccine for colorectal cancer did not demonstrate a molecular response difference from the control arm. Gritstone blames trial protocol and plans for a Phase III study.
PRESS RELEASES
Source plant is widely regarded as one of the most valuable fragrance raw materials in the world Stage 2 contract follows successful Stage 1 completion in March 2026
Key Regulatory Benchmark Met, Differentiating DMX-101 from Traditional Opioid Analgesics Late-Breaking Results to be Presented at CPDD 2026 Annual Meeting
Live virtual fireside chat — investors, advisors, and life sciences analysts invited to attend Featuring Dermatologist Mary Spellman, M.D., with Phio CEO Robert Bitterman and Force Family Office CEO Steven Saltzstein
· First-in-class oral mechanism triggers natural satiety hormones, addressing key limitations of GLP-1 therapies · Phase I data demonstrate fat mass reduction, preservation of lean mass, 80% responder rate, and no serious adverse events
